LacI-mediated sequence-specific affinity purification of plasmid DNA for therapeutic applications

ABSTRACT Affinity purification of plasmid DNA is an attractive option for the biomanufacture of therapeutic plasmids, which are strictly controlled for levels of host protein, DNA, RNA, and endotoxin. Plasmid vectors are considered to be a safer alternative than viruses for gene therapy, but milligr...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The FASEB journal 2005-05, Vol.19 (7), p.801-803
Hauptverfasser: Darby, Richard A. J, Hine, Anna V
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 803
container_issue 7
container_start_page 801
container_title The FASEB journal
container_volume 19
creator Darby, Richard A. J
Hine, Anna V
description ABSTRACT Affinity purification of plasmid DNA is an attractive option for the biomanufacture of therapeutic plasmids, which are strictly controlled for levels of host protein, DNA, RNA, and endotoxin. Plasmid vectors are considered to be a safer alternative than viruses for gene therapy, but milligram quantities of DNA are required per dose. Previous affinity approaches have involved triplex DNA formation and a sequence‐specific zinc finger protein. We present a more generically applicable protein‐based approach, which exploits the lac operator, present in a wide diversity of plasmids, as a target sequence. We used a GFP/His‐tagged LacI protein, which is precomplexed with the plasmid, and the resulting complex was immobilized on a solid support (TALON resin). Ensuing elution gives plasmid DNA, in good yield (>80% based on recovered starting material, 35–50% overall process), free from detectable RNA and protein and with minimal genomic DNA contamination. Such an affinity‐based process should enhance plasmid purity and ultimately, after appropriate development, may simplify the biomanufacturing process of therapeutic plasmids.
doi_str_mv 10.1096/fj.04-2812fje
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67794990</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67794990</sourcerecordid><originalsourceid>FETCH-LOGICAL-c397E-b153cedaf1fe3c8c14bf49ee57673b93a9a2c4ca7fd5c12bb5e6fcda04f5f9f73</originalsourceid><addsrcrecordid>eNqFkEFv1DAQhS0EotvCkSvkxM1lHDtOzK2UXWi1gkPp2XKcGfAquwl2IrT_Hq82Um9wGs3oe09vHmNvBFwLMPoD7a5B8bIRJe3wGVuJSgLXjYbnbAWNKbnWsrlglyntAECA0C_ZhahqncVmxdzW-Tu-xy64Cbsi4e8ZDx55GtEHCr5wROEQpmMxzvF0cFMYDsVAxdi7tA9d8fnbTUFDLKZfGN2I83QSjWO_oOkVe0GuT_h6mVfscbP-cfuVb79_ubu92XIvTb3mbQ7usXMkCKVvvFAtKYOYk9ayNdIZV3rlXU1d5UXZthVq8p0DRRUZquUVe3_2HeOQn0iT3Yfkse_dAYc5WV3XRhkD_wVFrTIodAb5GfRxSCki2TGGvYtHK8Ceyre0s6DsUn7m3y7Gc5sbfaKXtjPw8Qz8CT0e_-1mNw-fys09qNO-uV9n8buzmNxg3c8Ykn18KEFIAGNKUFr-BfF-ni4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17494916</pqid></control><display><type>article</type><title>LacI-mediated sequence-specific affinity purification of plasmid DNA for therapeutic applications</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Alma/SFX Local Collection</source><creator>Darby, Richard A. J ; Hine, Anna V</creator><creatorcontrib>Darby, Richard A. J ; Hine, Anna V</creatorcontrib><description>ABSTRACT Affinity purification of plasmid DNA is an attractive option for the biomanufacture of therapeutic plasmids, which are strictly controlled for levels of host protein, DNA, RNA, and endotoxin. Plasmid vectors are considered to be a safer alternative than viruses for gene therapy, but milligram quantities of DNA are required per dose. Previous affinity approaches have involved triplex DNA formation and a sequence‐specific zinc finger protein. We present a more generically applicable protein‐based approach, which exploits the lac operator, present in a wide diversity of plasmids, as a target sequence. We used a GFP/His‐tagged LacI protein, which is precomplexed with the plasmid, and the resulting complex was immobilized on a solid support (TALON resin). Ensuing elution gives plasmid DNA, in good yield (&gt;80% based on recovered starting material, 35–50% overall process), free from detectable RNA and protein and with minimal genomic DNA contamination. Such an affinity‐based process should enhance plasmid purity and ultimately, after appropriate development, may simplify the biomanufacturing process of therapeutic plasmids.</description><identifier>ISSN: 0892-6638</identifier><identifier>EISSN: 1530-6860</identifier><identifier>DOI: 10.1096/fj.04-2812fje</identifier><identifier>PMID: 15760969</identifier><language>eng</language><publisher>United States</publisher><subject>Bacterial Proteins - genetics ; DNA - isolation &amp; purification ; DNA vaccines ; Gene Expression ; gene therapy ; Genetic Therapy ; Genetic Vectors ; Green Fluorescent Proteins - genetics ; Histidine - genetics ; Lac Operon - genetics ; lac repressor protein ; Lac Repressors ; Mutation ; Plasmids - genetics ; protein-DNA interactions ; Recombinant Fusion Proteins ; Repressor Proteins - genetics ; Vaccines, DNA</subject><ispartof>The FASEB journal, 2005-05, Vol.19 (7), p.801-803</ispartof><rights>FASEB</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c397E-b153cedaf1fe3c8c14bf49ee57673b93a9a2c4ca7fd5c12bb5e6fcda04f5f9f73</citedby><cites>FETCH-LOGICAL-c397E-b153cedaf1fe3c8c14bf49ee57673b93a9a2c4ca7fd5c12bb5e6fcda04f5f9f73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1096%2Ffj.04-2812fje$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1096%2Ffj.04-2812fje$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15760969$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Darby, Richard A. J</creatorcontrib><creatorcontrib>Hine, Anna V</creatorcontrib><title>LacI-mediated sequence-specific affinity purification of plasmid DNA for therapeutic applications</title><title>The FASEB journal</title><addtitle>FASEB J</addtitle><description>ABSTRACT Affinity purification of plasmid DNA is an attractive option for the biomanufacture of therapeutic plasmids, which are strictly controlled for levels of host protein, DNA, RNA, and endotoxin. Plasmid vectors are considered to be a safer alternative than viruses for gene therapy, but milligram quantities of DNA are required per dose. Previous affinity approaches have involved triplex DNA formation and a sequence‐specific zinc finger protein. We present a more generically applicable protein‐based approach, which exploits the lac operator, present in a wide diversity of plasmids, as a target sequence. We used a GFP/His‐tagged LacI protein, which is precomplexed with the plasmid, and the resulting complex was immobilized on a solid support (TALON resin). Ensuing elution gives plasmid DNA, in good yield (&gt;80% based on recovered starting material, 35–50% overall process), free from detectable RNA and protein and with minimal genomic DNA contamination. Such an affinity‐based process should enhance plasmid purity and ultimately, after appropriate development, may simplify the biomanufacturing process of therapeutic plasmids.</description><subject>Bacterial Proteins - genetics</subject><subject>DNA - isolation &amp; purification</subject><subject>DNA vaccines</subject><subject>Gene Expression</subject><subject>gene therapy</subject><subject>Genetic Therapy</subject><subject>Genetic Vectors</subject><subject>Green Fluorescent Proteins - genetics</subject><subject>Histidine - genetics</subject><subject>Lac Operon - genetics</subject><subject>lac repressor protein</subject><subject>Lac Repressors</subject><subject>Mutation</subject><subject>Plasmids - genetics</subject><subject>protein-DNA interactions</subject><subject>Recombinant Fusion Proteins</subject><subject>Repressor Proteins - genetics</subject><subject>Vaccines, DNA</subject><issn>0892-6638</issn><issn>1530-6860</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkEFv1DAQhS0EotvCkSvkxM1lHDtOzK2UXWi1gkPp2XKcGfAquwl2IrT_Hq82Um9wGs3oe09vHmNvBFwLMPoD7a5B8bIRJe3wGVuJSgLXjYbnbAWNKbnWsrlglyntAECA0C_ZhahqncVmxdzW-Tu-xy64Cbsi4e8ZDx55GtEHCr5wROEQpmMxzvF0cFMYDsVAxdi7tA9d8fnbTUFDLKZfGN2I83QSjWO_oOkVe0GuT_h6mVfscbP-cfuVb79_ubu92XIvTb3mbQ7usXMkCKVvvFAtKYOYk9ayNdIZV3rlXU1d5UXZthVq8p0DRRUZquUVe3_2HeOQn0iT3Yfkse_dAYc5WV3XRhkD_wVFrTIodAb5GfRxSCki2TGGvYtHK8Ceyre0s6DsUn7m3y7Gc5sbfaKXtjPw8Qz8CT0e_-1mNw-fys09qNO-uV9n8buzmNxg3c8Ykn18KEFIAGNKUFr-BfF-ni4</recordid><startdate>200505</startdate><enddate>200505</enddate><creator>Darby, Richard A. J</creator><creator>Hine, Anna V</creator><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TM</scope><scope>7X8</scope></search><sort><creationdate>200505</creationdate><title>LacI-mediated sequence-specific affinity purification of plasmid DNA for therapeutic applications</title><author>Darby, Richard A. J ; Hine, Anna V</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c397E-b153cedaf1fe3c8c14bf49ee57673b93a9a2c4ca7fd5c12bb5e6fcda04f5f9f73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Bacterial Proteins - genetics</topic><topic>DNA - isolation &amp; purification</topic><topic>DNA vaccines</topic><topic>Gene Expression</topic><topic>gene therapy</topic><topic>Genetic Therapy</topic><topic>Genetic Vectors</topic><topic>Green Fluorescent Proteins - genetics</topic><topic>Histidine - genetics</topic><topic>Lac Operon - genetics</topic><topic>lac repressor protein</topic><topic>Lac Repressors</topic><topic>Mutation</topic><topic>Plasmids - genetics</topic><topic>protein-DNA interactions</topic><topic>Recombinant Fusion Proteins</topic><topic>Repressor Proteins - genetics</topic><topic>Vaccines, DNA</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Darby, Richard A. J</creatorcontrib><creatorcontrib>Hine, Anna V</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Nucleic Acids Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The FASEB journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Darby, Richard A. J</au><au>Hine, Anna V</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>LacI-mediated sequence-specific affinity purification of plasmid DNA for therapeutic applications</atitle><jtitle>The FASEB journal</jtitle><addtitle>FASEB J</addtitle><date>2005-05</date><risdate>2005</risdate><volume>19</volume><issue>7</issue><spage>801</spage><epage>803</epage><pages>801-803</pages><issn>0892-6638</issn><eissn>1530-6860</eissn><abstract>ABSTRACT Affinity purification of plasmid DNA is an attractive option for the biomanufacture of therapeutic plasmids, which are strictly controlled for levels of host protein, DNA, RNA, and endotoxin. Plasmid vectors are considered to be a safer alternative than viruses for gene therapy, but milligram quantities of DNA are required per dose. Previous affinity approaches have involved triplex DNA formation and a sequence‐specific zinc finger protein. We present a more generically applicable protein‐based approach, which exploits the lac operator, present in a wide diversity of plasmids, as a target sequence. We used a GFP/His‐tagged LacI protein, which is precomplexed with the plasmid, and the resulting complex was immobilized on a solid support (TALON resin). Ensuing elution gives plasmid DNA, in good yield (&gt;80% based on recovered starting material, 35–50% overall process), free from detectable RNA and protein and with minimal genomic DNA contamination. Such an affinity‐based process should enhance plasmid purity and ultimately, after appropriate development, may simplify the biomanufacturing process of therapeutic plasmids.</abstract><cop>United States</cop><pmid>15760969</pmid><doi>10.1096/fj.04-2812fje</doi><tpages>3</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0892-6638
ispartof The FASEB journal, 2005-05, Vol.19 (7), p.801-803
issn 0892-6638
1530-6860
language eng
recordid cdi_proquest_miscellaneous_67794990
source MEDLINE; Access via Wiley Online Library; Alma/SFX Local Collection
subjects Bacterial Proteins - genetics
DNA - isolation & purification
DNA vaccines
Gene Expression
gene therapy
Genetic Therapy
Genetic Vectors
Green Fluorescent Proteins - genetics
Histidine - genetics
Lac Operon - genetics
lac repressor protein
Lac Repressors
Mutation
Plasmids - genetics
protein-DNA interactions
Recombinant Fusion Proteins
Repressor Proteins - genetics
Vaccines, DNA
title LacI-mediated sequence-specific affinity purification of plasmid DNA for therapeutic applications
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-26T13%3A51%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=LacI-mediated%20sequence-specific%20affinity%20purification%20of%20plasmid%20DNA%20for%20therapeutic%20applications&rft.jtitle=The%20FASEB%20journal&rft.au=Darby,%20Richard%20A.%20J&rft.date=2005-05&rft.volume=19&rft.issue=7&rft.spage=801&rft.epage=803&rft.pages=801-803&rft.issn=0892-6638&rft.eissn=1530-6860&rft_id=info:doi/10.1096/fj.04-2812fje&rft_dat=%3Cproquest_cross%3E67794990%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17494916&rft_id=info:pmid/15760969&rfr_iscdi=true